Entity Details

Primary name CLCKA_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP51800
EntryNameCLCKA_HUMAN
FullNameChloride channel protein ClC-Ka
TaxID9606
Evidenceevidence at protein level
Length687
SequenceStatuscomplete
DateCreated1996-10-01
DateModified2021-06-02

Ontological Relatives

GenesCLCNKA

GO terms

Show/Hide Table
GOName
GO:0005247 voltage-gated chloride channel activity
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0006821 chloride transport
GO:0007588 excretion
GO:0034220 ion transmembrane transport
GO:0034707 chloride channel complex
GO:0034765 regulation of ion transmembrane transport
GO:0042802 identical protein binding
GO:0046872 metal ion binding

Subcellular Location

Show/Hide Table
Subcellular Location
Membrane

Domains

Show/Hide Table
DomainNameCategoryType
IPR000644 CBS domainDomainDomain
IPR001807 Chloride channel, voltage gatedFamilyFamily
IPR002250 Chloride channel ClC-KFamilyFamily
IPR014743 Chloride channel, coreFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
613090 OMIMBartter syndrome 4B, neonatal, with sensorineural deafness (BARTS4B)A digenic form of Bartter syndrome, an autosomal recessive disorder characterized by impaired salt reabsorption in the thick ascending loop of Henle with pronounced salt wasting, hypokalemic metabolic alkalosis, and varying degrees of hypercalciuria. BARTS4B is associated with sensorineural deafness. The disease is caused by variants affecting distinct genetic loci, including the gene represented in this entry. Loss-of-function of both CLCNKA and CLCNKB results in the disease phenotype (PubMed:18310267).

Drugs

Show/Hide Table
DrugNameSourceType
DB04552 Niflumic acidDrugbanksmall molecule
DB09295 TalniflumateDrugbanksmall molecule